EAF2: A Membrane Protein as A Drug Target (G55840)

Target Name: EAF2

NCBI ID: G55840

EAF2

EAF2: A Membrane Protein as A Drug Target

The endoplasmic reticulum (ER) is a membrane-enclosed organelle that contains many different types of membrane proteins. Membrane proteins are one of the most important proteins in cells, and they participate in many intracellular biochemical reactions. However, membrane proteins may also be targets for drug development because they serve as drug targets. This article will introduce a membrane protein called EAF2 and study its potential as a drug target and its research progress.

Structure and function of EAF2

EAF2 is a membrane protein belonging to the glycoprotein family, and its encoding gene is located on human chromosome 1p36.1. EAF2 has widespread expression in cell membranes and can be detected in many different cell types.

The relationship between the structure and function of EAF2 is very close. EAF2 is composed of two main polypeptide chains, each containing an intracellular domain and an extracellular domain. The intracellular domain consists of an N-terminal 伪-helix, a central 尾-sheet, and a C-terminal domain. The extracellular domain consists of an N-terminal 伪-helix, a central 尾-sheet, and a C-terminal domain. In addition, EAF2 also contains a modification region, including phosphorylation of a serine residue, ubiquitination of a glutamic acid residue, and modification of an alanine residue.

The main function of EAF2 is to participate in cell signaling and cell adhesion. Within cells, EAF2 interacts with many different proteins, including 尾2-transferrin, integrins, and FAK. These proteins interact with the extracellular domain of EAF2, enhancing the stability and accessibility of EAF2 at the cell membrane.

Pharmacological potential of EAF2

EAF2 is a membrane protein with broad pharmacological potential and can serve as a target for many different types of drugs. First, EAF2 is a good drug target because it is overexpressed in multiple tumor types, including breast, lung, and prostate cancers. In addition, EAF2 is also closely related to the occurrence and development of many diseases, including inflammation, oxidative stress, and neurodegenerative diseases.

Currently, a variety of drugs have entered clinical research to inhibit the function of EAF2 and treat various tumors. For example, the anti-integrin drug Adatanib is a targeted tumor treatment drug that has been used to treat a variety of tumors, including breast cancer, lung cancer, and kidney cancer. In addition, the anti-inflammatory drug nicardin (Nicardin) is also a targeted tumor treatment drug and has been used to treat a variety of inflammatory diseases, including rheumatoid arthritis and other inflammatory diseases.

Biological studies of EAF2

EAF2 is of great significance in biological research. Many studies have shown that EAF2 expression in multiple tumor types upregulates tumor growth and progression. In addition, EAF2 is also closely related to the invasion and metastasis ability of tumor cells.

Studies have shown that overexpression of EAF2 is an important factor in tumor cell invasion and metastasis. In breast cancer, up-regulation of EAF2 expression is closely related to the enhanced invasion and metastasis capabilities of breast cancer. In addition, in lung cancer, the increased expression of EAF2 is also closely related to the enhanced invasion and metastasis ability of lung cancer.

EAF2 is also closely related to the immunogenicity of tumor cells. Studies have shown that EAF2 can enhance the immunogenicity of tumor cells, thereby enhancing the ability of tumor cells to escape immune cells. In addition, EAF2 can also regulate immune cell functions, including T cell activation and proliferation.

Clinical applications of EAF2

EAF2 is a membrane protein with broad clinical application prospects. Currently, a variety of drugs have entered clinical research to inhibit the function of EAF2 and treat various tumors. In addition, EAF2 is also closely related to the occurrence and development of a variety of diseases, including inflammation, oxidative stress, and neurodegenerative diseases. Therefore, EAF2 is an important drug target and can be targeted for drug development.

in conclusion

EAF2 is an important membrane protein with a wide range of biological functions in cell signaling and cell adhesion. In addition, EAF2 is a good drug target and can be used as a target for drug development to treat various tumors. Currently, a variety of drugs have entered clinical research to inhibit the function of EAF2 and treat various tumors. Therefore, EAF2 is a membrane protein with broad clinical application prospects and can be used as a target for drug development.

Protein Name: ELL Associated Factor 2

Functions: Acts as a transcriptional transactivator of TCEA1 elongation activity (By similarity). Acts as a transcriptional transactivator of ELL and ELL2 elongation activities. Potent inducer of apoptosis in prostatic and non-prostatic cell lines. Inhibits prostate tumor growth in vivo

The "EAF2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EAF2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets